Dr. Dohrmann has served as the company’s CSO and a member of the Management Board since 2010. During his tenure, he was instrumental in scaling the firm’s research infrastructure, specifically overseeing the integration of iPSC-based technologies and advanced omics capabilities. CEO Dr. Christian Wojczewski credited Dohrmann with fostering a culture of innovation that remains central to the company’s current platform-led strategy.

Reflecting on his departure, Dohrmann noted the shift in drug discovery landscapes over the last decade and expressed confidence in the company’s ongoing trajectory. Evotec, which employs approximately 4,500 people globally and maintains partnerships with major pharmaceutical players, continues its focus on oncology, neurology, and immunology. The company has not yet provided a shortlist of candidates to fill the upcoming vacancy.